In the recent past, it has repeatedly been reported that CD4 cells play an important role in the immunology of chronic myeloid leukaemia. It was therefore of interest to test their activity in an animal model using bcr-abl-transformed cells. BALB/c mice were four times immunized with a DNA vaccine carrying the bcr-abl fusion gene. Two weeks after the last vaccine dose, the animals were challenged with syngeneic bcr-abl-transformed 12B1 cells which form solid tumors after subcutaneous administration. At the time of challenge, animals were treated with antibodies against the CD8+ T cells or CD4+ T cells. The efficacy of the depletion was monitored and found highly effective. All nonimmunized animals developed tumors. All animals untreated with the antibodies as well as those in which CD8+ T cells had been depleted, were fully protected against the challenge. On the other hand, almost all mice treated with anti-CD4+ antibody developed tumors. These results strongly suggested that the CD4+ T cells acted as effectors in the present system.

• MeSH
• antigeny CD95 imunologie   metabolismus   MeSH
• bcr-abl fúzní proteiny genetika   imunologie   MeSH
• CD4-pozitivní T-lymfocyty imunologie   metabolismus   MeSH
• CD8-pozitivní T-lymfocyty imunologie   metabolismus   MeSH
• DNA vakcíny imunologie   MeSH
• imunizace MeSH
• lidé MeSH
• ligand Fas metabolismus   MeSH
• lymfocytární deplece MeSH
• MHC antigeny II. třídy imunologie   metabolismus   MeSH
• modely nemocí na zvířatech MeSH
• myši MeSH
• nádorová transformace buněk genetika   imunologie   MeSH
• nádory genetika   imunologie   mortalita   prevence a kontrola   MeSH
• protinádorové vakcíny genetika   imunologie   MeSH
• slezina cytologie   imunologie   MeSH
• transformované buněčné linie MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antigeny CD95 MeSH
• bcr-abl fúzní proteiny MeSH
• DNA vakcíny MeSH
• ligand Fas MeSH
• MHC antigeny II. třídy MeSH
• protinádorové vakcíny MeSH